Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diastase + pepsin
- Development stage
- Unknown
- Lead developer
- Amvia Biotech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
AMVOZYME is a digestive enzyme preparation developed by Amvia Biotech, formulated as an oral syrup. It contains a combination of diastase (50 mg) and pepsin (10 mg). Diastase is an amylolytic enzyme that assists in the breakdown of starch and complex carbohydrates into simpler sugars, while pepsin is a proteolytic enzyme that aids in the digestion of proteins into smaller peptides. This combination is primarily indicated for the treatment of dyspepsia (indigestion) and digestive enzyme insufficiency, helping to improve nutrient absorption and alleviate symptoms like bloating and abdominal discomfort.
- Brand names
- AMVOZYME
- Other names
- diastase + pepsin
Beyond the preview
Go deeper on diastase + pepsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diastase + pepsin.